Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DC-based cancer vaccines.

Eli Gilboa1

  • 1Department of Microbiology and Immunology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, 1550 NW 10th Avenue Medical Campus, Miami, FL 33136, USA. egilboa@med.miami.edu

The Journal of Clinical Investigation
|May 4, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vaccination Against Pathogens Targeting Cell-Derived Cryptic Antigens.

The Journal of infectious diseases·2025
Same author

KLF2 inhibition expands tumor-resident T cells and enhances tumor immunity.

Research square·2025
Same author

Vaccination against neoantigens induced in cross-priming cDC1 in vivo.

Cancer immunology, immunotherapy : CII·2024
Same author

Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer.

Cancer research communications·2023
Same author

The Quest for mRNA Vaccines.

Nucleic acid therapeutics·2022
Same author

Author Correction: Hapten-mediated recruitment of polyclonal antibodies to tumors engenders antitumor immunity.

Nature communications·2021

Developing effective cancer vaccines requires potent protocols. Ex vivo dendritic cell (DC) vaccination, loaded with tumor antigens, offers a superior method for stimulating antitumor immunity compared to direct vaccination.

Area of Science:

  • Immunology
  • Oncology
  • Vaccine Development

Background:

  • Tumors present a significant antigenic load and create an immunosuppressive environment.
  • Therapeutic antitumor immunity in cancer patients necessitates powerful vaccination strategies.
  • Conventional vaccination methods face challenges in overcoming tumor-induced immunosuppression.

Purpose of the Study:

  • To evaluate the potential of ex vivo dendritic cell (DC) vaccination for stimulating antitumor immunity.
  • To compare the efficacy of DC-based tumor vaccines with conventional direct vaccination methods.
  • To explore the advantages of ex vivo manipulation of DCs for cancer immunotherapy.

Main Methods:

  • Loading autologous dendritic cells (DCs) ex vivo with tumor antigens.

Related Experiment Videos

  • Administering antigen-loaded DCs to cancer patients as a vaccination strategy.
  • Comparing the immune response generated by ex vivo DC vaccination versus direct vaccination.

    • Main Results:

    • Ex vivo manipulation of DCs generates a highly potent antigen-presenting cell (APC).
    • DC-based vaccination demonstrates superior potential for stimulating antitumor immunity in vivo.
    • This approach offers enhanced control and efficiency in the vaccination process.

    Conclusions:

    • Ex vivo dendritic cell vaccination represents a promising and powerful approach for cancer immunotherapy.
    • This customized cell therapy method may overcome limitations of conventional tumor vaccines.
    • Further research is warranted to optimize DC vaccination protocols despite added complexity and cost.